文献速递肝病消化内镜

RESIST-HCV标准监测丙型肝炎病毒清除后代偿性肝硬化低风险食管静脉曲张进展:SIMPLE研究:SIMPLE:监测低风险食管静脉曲张进展的评分指数

RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices.
PubMed 文献 · Am J Gastroenterol · 2022-07-21

本研究在3个转诊中心纳入353例经直接抗病毒药物(DAA)获得持续病毒学应答(SVR)的代偿性丙型肝炎病毒(HCV)肝硬化患者,评估RESIST-HCV标准预测高风险静脉曲张(HRV)进展的诊断性能。平均随访44.2个月,34例(9.6%,95%CI 6.7%-13.5%)进展为HRV。RESIST-HCV标准的受试者工作特征曲线下面积最高(0.70,95%CI 0.65-0.75),正确避免内镜检查比例最高(54.3%),假阳性率最低(45.7%),决策曲线分析显示其临床效用高于基于弹性成像的标准。

要点

  • RESIST-HCV标准基于血小板>120×10^9/L且血清白蛋白>3.6 g/dL判定为低风险。
  • RESIST-HCV标准的AUC为0.70(95%CI 0.65-0.75),高于基于弹性成像的标准。
  • RESIST-HCV标准正确避免54.3%的内镜检查,假阳性率45.7%。

核心结论

  • 基于生化指标的RESIST-HCV标准可用于简单预测经DAA清除HCV后代偿性肝硬化及低风险食管静脉曲张患者HRV的发生。

研究设计与样本

  • 在3个转诊中心连续观察的代偿性HCV肝硬化患者(伴或不伴F1级食管静脉曲张)中,经DAA获得SVR者纳入研究。
  • 共纳入353例Child-Pugh A级患者,平均年龄67.2岁,男性占53.8%。
  • 根据末次食管胃十二指肠镜检查(EGDS)时血小板>120×10^9/L且血清白蛋白>3.6 g/dL判定为RESIST-HCV低风险,血小板<120×10^9/L或血清白蛋白<3.6 g/dL判定为RESIST-HCV高风险。
  • 主要结局为进展至高风险静脉曲张(HRV)。
  • 计算非侵入性标准的受试者工作特征曲线下面积及决策曲线分析。

主要发现

  • 平均随访44.2个月期间,34例患者(9.6%,95%CI 6.7%-13.5%)进展为HRV。
  • 末次EGDS时,178例(50.4%)为RESIST-HCV低风险,175例(49.6%)为RESIST-HCV高风险。
  • 与基于弹性成像的标准相比,RESIST-HCV标准的受试者工作特征曲线下面积最高(0.70,95%CI 0.65-0.75)。
  • RESIST-HCV标准正确避免EGDS的数量最多(54.3%),假阳性率最低(45.7%)。
  • 决策曲线分析显示RESIST-HCV标准的临床效用高于基于弹性成像的标准。

关键数值与推荐

  • RESIST-HCV低风险定义为血小板>120×10^9/L且血清白蛋白>3.6 g/dL。
  • RESIST-HCV高风险定义为血小板<120×10^9/L或血清白蛋白<3.6 g/dL。
  • RESIST-HCV标准的AUC为0.70(95%CI 0.65-0.75)。
  • RESIST-HCV标准正确避免EGDS的比例为54.3%,假阳性率为45.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Noninvasive criteria to predict the progression of low-risk esophageal varices (EV) in patients with compensated hepatitis C virus (HCV) cirrhosis after sustained virological response (SVR) by direct-acting antivirals (DAAs) are lacking. Our aim was to assess the diagnostic performance of Rete Sicilia Selezione Terapia-HCV (RESIST-HCV) criteria for EV progression compared with elastography-based criteria (Baveno VI, Expanded Baveno VI, and Baveno VII-HCV criteria). METHODS: All consecutive patients observed at 3 referral centers with compensated HCV cirrhosis with or without F1 EV who achieved sustained virological response by DAAs were classified at last esophagogastroduodenoscopy (EGDS) as RESIST-HCV low risk (i.e., low probability of high-risk varices [HRV]) if platelets were >120 × 10 9 /L and serum albumin >3.6 g/dL or RESIST-HCV high risk (i.e., high probability of HRV) if platelets were <120 × 10 9 /L or serum albumin <3.6 g/dL. The primary outcome was the progression to HRV. The area under the receiver operating characteristic curve and decision curve analysis of noninvasive criteria were calculated. RESULTS: The cohort consisted of 353 patients in Child-Pugh class A (mean age 67.2 years, 53.8% males). During a mean follow-up of 44.2 months, 34 patients (9.6%, 95% CI 6.7%-13.5%) developed HRV. At the last EGDS, 178 patients (50.4%) were RESIST-low risk, and 175 (49.6%) were RESIST-high risk. RESIST-HCV criteria showed the highest area under the receiver operating characteristic curve (0.70, 95% confidence interval 0.65-0.75), correctly sparing the highest number of EGDS (54.3%), with the lowest false-positive rate (45.7%), compared with elastography-based criteria. Decision curve analysis showed that RESIST-HCV had higher clinical utility than elastography-based criteria. DISCUSSION: Biochemical-based RESIST-HCV criteria are useful to easily predict HRV development after HCV eradication by DAAs in patients with compensated cirrhosis and low-risk EV.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Calvaruso V, Celsa C, D'Ambrosio R, et al. RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices. Am J Gastroenterol. 2022. PMID: 35973181. doi:10.14309/ajg.0000000000001878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。